A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena

Lancet. 2023 Aug 12;402(10401):504-505. doi: 10.1016/S0140-6736(23)01182-0. Epub 2023 Jun 26.

Authors

Stephen C Bain¹, Thinzar Min²

Affiliations

¹ Swansea Bay University Health Board and Swansea University Medical School, Swansea SA2 8PP, UK. Electronic address: s.c.bain@swansea.ac.uk.
² Swansea Bay University Health Board and Swansea University Medical School, Swansea SA2 8PP, UK.

PMID: 37385276
DOI: 10.1016/S0140-6736(23)01182-0

No abstract available

Publication types

Comment

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide 1
Glucose
Humans
Hypoglycemic Agents / therapeutic use
Incretins* / therapeutic use
Insulin

Substances

Incretins
Glucose
Hypoglycemic Agents
Glucagon-Like Peptide 1
Blood Glucose
Insulin